Health Tech Unicorns: The Leading Private Healthcare Technology Companies in 2026

Healthcare is the largest sector of the US economy and one of the largest in most developed countries, yet it remains slow, expensive and fragmented. Health technology companies try to fix pieces of the system: insurance and care delivery, primary care, chronic disease management, mental health, data and administrative work. Many raised large rounds during the 2020–2021 digital health boom, and a new generation has raised since, often with a focus on AI and measurable savings. This guide ranks the private health tech unicorns in our database by sourced valuation and explains the main business models, the post-pandemic reset and what investors and buyers look for.

Every company in the table links to a full profile with its sourced valuation, funding history and investors. We focus on companies that deliver care, coordinate care, manage health data or sell to healthcare payers and providers. Healthcare AI companies such as Abridge and OpenEvidence are covered in our guide to healthcare AI startups.

The ranking

Insurance and value-based care

Several of the most valuable companies take responsibility for patients' total cost of care. Devoted Health, valued at about US$16 billion in early 2026 according to reports, is a Medicare Advantage insurer that also provides care, aiming to keep older adults healthier. Cityblock Health, reportedly valued at US$5.7 billion in 2021, provides primary, behavioural and social care to people on Medicaid. Aledade, reportedly valued at US$3.5 billion, helps independent primary care practices succeed in value-based contracts with Medicare and insurers. These companies earn more when patients stay healthy and avoid expensive hospital care, aligning financial incentives with better health.

Direct-to-patient care

Ro, valued at US$7 billion, provides telehealth and medications directly to patients for conditions such as weight management, sexual health and hair loss, with a large GLP-1 weight loss programme. Function Health, valued at US$2.5 billion, sells memberships that include extensive lab testing and health insights. Direct-to-consumer health companies can grow quickly through marketing, but they face regulatory scrutiny and must show that their services are medically appropriate.

Employer and health plan benefits

Many health tech companies sell to employers and health plans that pay for employees' care. Lyra Health and Spring Health provide mental health benefits. Sword Health, valued at US$4 billion, offers AI-guided physical therapy and other care programmes. Virta Health, valued at US$2 billion in 2021, treats type 2 diabetes through supervised nutrition. Garner Health, valued at US$2.74 billion after a May 2026 round, helps employees find high-quality doctors and covers their out-of-pocket costs. Headway helps therapists accept insurance. These companies must prove to employers and health plans that they improve outcomes and reduce costs, often through outcome-based pricing.

Health data and operations

Commure, reportedly valued at about US$7 billion, builds AI and software for health system operations, including ambient documentation and revenue cycle management. Komodo Health, valued at US$3.3 billion in 2021, maps patient journeys using de-identified data for life sciences companies. Truveta, owned largely by health systems and valued at more than US$1 billion, provides clinical data for research and is building a large genome project with Regeneron. Data and administrative software are attractive because healthcare spends enormous sums on administration and needs better information for research and decisions.

The digital health boom and reset

Digital health funding peaked in 2021, when telehealth soared during the pandemic and investors paid high valuations for growth. In 2022 and 2023, funding fell sharply, public digital health companies lost much of their value, and some private companies cut staff, merged or shut down. Value-based care companies that had gone public, such as several primary care operators, struggled with rising medical costs. Since then, investors have favoured companies with clear paths to profitability, evidence of savings and AI that reduces administrative work. Several valuations in our table date from 2021, so readers should check the date column.

Who pays in healthcare

Understanding who pays is essential in health tech. In the US, the main payers are government programmes such as Medicare and Medicaid, private health insurers and self-insured employers, with patients paying part of the cost directly. Each payer has different incentives and buying processes. Selling to health systems and insurers often involves long sales cycles and complex contracts. Companies that sell directly to consumers avoid some of this complexity but must persuade individuals to pay. Many successful health tech companies find a payer whose costs they can reduce and design their pricing around that value.

The role of GLP-1 medications

GLP-1 drugs for weight loss and diabetes have reshaped parts of the health tech market. Telehealth companies such as Ro grew rapidly by prescribing them, while employers and insurers face large new costs. Companies such as Virta and other chronic care programmes position themselves as helping manage these costs and support patients. How payers cover GLP-1 drugs, and how prices change, will significantly affect several companies in this guide.

AI in healthcare delivery

AI is being applied across healthcare: documentation, coding and billing, patient communication, triage, care management and research. For health tech companies, AI can lower the cost of delivering care, allowing clinicians to serve more patients, as in Sword Health's model, or reduce administrative burdens, as with Commure's tools. Regulators and professional bodies are developing rules for clinical AI, and companies must demonstrate safety and effectiveness.

How to evaluate a health tech company

Key questions include who pays and why, what evidence shows clinical and financial results, how the company acquires customers, how much financial risk it carries under value-based contracts, and how regulation and reimbursement rules affect it. Independent studies and audited savings carry more weight than company claims. For older valuations, consider how the company has performed since the 2021 peak.

What to watch

Watch Medicare and Medicaid policy changes, GLP-1 coverage decisions, IPO plans from companies such as Sword Health and Devoted Health, AI adoption in care delivery, and new funding rounds that update older valuations. Our guides to healthcare AI startups, mental health startups and wearable health companies cover related areas.

Key takeaways

Devoted Health, Ro and Commure lead private health tech by valuation, followed by Cityblock, Lyra and Sword Health. The sector spans insurance, value-based care, direct-to-patient services, employer benefits and data. After the 2021 boom, investors now favour companies that can prove savings, reach profitability and use AI to reduce costs.

Lessons from public digital health companies

Several digital health companies went public during the 2020–2021 boom, and their experience offers lessons for private companies. Telehealth and chronic care companies that grew rapidly during the pandemic often saw growth slow and share prices fall sharply. Value-based primary care operators faced rising medical costs that turned expected profits into losses. Some companies were acquired at far lower values than their peak market capitalisations. The common lesson is that healthcare businesses must prove sustainable economics, including clinical outcomes, customer retention and control of medical costs, not just rapid growth. Private companies preparing for IPOs, such as Sword Health and Devoted Health, are being judged by these standards.

Partnerships with health systems

Many health tech companies depend on partnerships with hospitals and health systems, whether selling software to them, as Commure does, or using their data, as Truveta does. Health systems move slowly, with long procurement processes and complex IT environments, but once a technology is embedded, relationships can last for years. Companies that understand clinical workflows and can demonstrate value to both clinicians and administrators tend to win these partnerships.